Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Evaluation of Efficacy at 2 Weeks of Duac® Fixed Dose Combination Gel in Treatment of Facial Acne Vulgaris in Japanese Subjects
Brief Summary: This is a multicentre, randomized, single-blind (investigator is blinded), active (the combination therapy of adapalene \[ADA\] and clindamycin \[CLDM\])-controlled and parallel-group study in Japanese subjects with facial acne vulgaris. The purpose of this study is to evaluate the efficacy, safety and tolerability of CLDM 1 percent (%)-benzoyl peroxide 3% (Duac®: trademark owned by GlaxoSmithKline) once daily fixed dose combination gel versus combination therapy of ADA 0.1% gel and CLDM 1% gel in the topical treatment of facial acne vulgaris for 12 weeks. A total of 400 subjects will be screened for enrolment. Subjects will use Duac® fixed dose combination gel with quantity sufficient to cover entire face (including the forehead, nose, cheeks and chin) once daily in the evening (at bedtime) or combination therapy of ADA 0.1% gel with quantity sufficient to cover entire face (including the forehead, nose, cheeks and chin) once daily in the evening (at bedtime) and CLDM 1% gel twice daily, once in the morning and once in the evening (at bedtime) for 12 weeks.


Options:
A: Arm Label: Adapalene/Benzoyl Peroxide Gel; Type: EXPERIMENTAL; Interventions: Drug: Adapalene/Benzoyl Peroxide | Arm Label: Adapalene Gel, 0.1%; Type: EXPERIMENTAL; Interventions: Drug: Adapalene Gel, 0.1% | Arm Label: Benzoyl Peroxide Gel 2.5%; Type: EXPERIMENTAL; Interventions: Drug: Benzoyl Peroxide Gel 2.5% | Arm Label: Gel Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Gel Vehicle | Intervention Type: DRUG; Name: Adapalene/Benzoyl Peroxide; Assigned to Arm(s): Adapalene/Benzoyl Peroxide Gel | Intervention Type: DRUG; Name: Adapalene Gel, 0.1%; Assigned to Arm(s): Adapalene Gel, 0.1% | Intervention Type: DRUG; Name: Benzoyl Peroxide Gel 2.5%; Assigned to Arm(s): Benzoyl Peroxide Gel 2.5% | Intervention Type: DRUG; Name: Gel Vehicle; Assigned to Arm(s): Gel Vehicle
B: Arm Label: Duac & taz; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene | Arm Label: Acanya & taz; Type: ACTIVE_COMPARATOR; Interventions: Drug: clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene | Intervention Type: DRUG; Name: Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene; Assigned to Arm(s): Duac & taz | Intervention Type: DRUG; Name: clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene; Assigned to Arm(s): Acanya & taz
C: Arm Label: CD0271 0.3% /CD1579 2.5% Gel; Type: EXPERIMENTAL; Interventions: Drug: CD0271 0.3% / CD1579 2.5% | Arm Label: CD0271 0.1% / CD1579 2.5%; Type: ACTIVE_COMPARATOR; Interventions: Drug: CD0271 0.1% / CD1579 2.5% | Arm Label: Topical Gel Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Topical Gel Vehicle | Intervention Type: DRUG; Name: CD0271 0.3% / CD1579 2.5%; Assigned to Arm(s): CD0271 0.3% /CD1579 2.5% Gel | Intervention Type: DRUG; Name: CD0271 0.1% / CD1579 2.5%; Assigned to Arm(s): CD0271 0.1% / CD1579 2.5% | Intervention Type: DRUG; Name: Topical Gel Vehicle; Assigned to Arm(s): Topical Gel Vehicle
D: Arm Label: Duac® fixed dose combination gel; Type: EXPERIMENTAL; Interventions: Drug: Duac® fixed dose combination gel | Arm Label: Combination therapy: ADA 0.1% gel + CLDM 1% gel; Type: ACTIVE_COMPARATOR; Interventions: Drug: ADA 0.1% gel, Drug: CLDM 1% gel | Intervention Type: DRUG; Name: Duac® fixed dose combination gel; Assigned to Arm(s): Duac® fixed dose combination gel | Intervention Type: DRUG; Name: ADA 0.1% gel; Assigned to Arm(s): Combination therapy: ADA 0.1% gel + CLDM 1% gel | Intervention Type: DRUG; Name: CLDM 1% gel; Assigned to Arm(s): Combination therapy: ADA 0.1% gel + CLDM 1% gel

Answer: D